PVLA Stock Price, Analysis & Fundamentals | Palvella Therapeutics, Inc.

Analysis

Palvella Therapeutics, Inc. is a healthcare company operating in the biotechnology industry. With a market capitalization of $1.05 billion and 14 employees, it has a relatively small scale compared to other companies in its sector. The company's financial health is marked by significant losses, with a net income of -$32,370,000 in the trailing twelve months (TTM). Its operating margins, profit margin, gross margin, EBITDA, revenue, and free cash flow are all zero or negative. The return on equity (ROE) and return on assets (ROA) are also significantly negative at -301.2% and -47.5%, respectively. Palvella Therapeutics has $63.57 million in cash and $16.02 million in debt, resulting in a debt-to-equity ratio of 41.42. The company's valuation is characterized by a forward price-to-earnings (P/E) ratio of -21.87 and a price-to-book ratio of 25.35.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania

Visit website →

PVLA

Price History (1Y)

Analysis

About Palvella Therapeutics, Inc.

Key Statistics

Company Info